Literature DB >> 34397577

Description and management of retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor therapy.

Nita G Valikodath1, Michael F Chiang2, R V Paul Chan1.   

Abstract

PURPOSE OF REVIEW: To review the literature regarding reactivation of retinopathy of prematurity (ROP) after treatment with antivascular endothelial growth factor (anti-VEGF) agents. RECENT
FINDINGS: Reactivation can occur after anti-VEGF or laser. Risk factors for reactivation include patient and disease-related factors. Various studies are evaluating the use of different anti-VEGF agents and reactivation rates. However, the definition of reactivation varies between studies.
SUMMARY: The literature has varied definitions of reactivation, which is often used interchangeably with recurrence. It is important to recognize features of reactivation of ROP to appropriately manage patients and conduct clinical trials. The International Classification of ROP 3rd edition has established a consensus guideline regarding terminology describing reactivation.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34397577      PMCID: PMC8514167          DOI: 10.1097/ICU.0000000000000786

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   4.299


  47 in total

Review 1.  Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity.

Authors:  Deborah K VanderVeen; Sule U Cataltepe
Journal:  Semin Perinatol       Date:  2019-05-10       Impact factor: 3.300

2.  Efficacy of Primary Intravitreal Ranibizumab for Retinopathy of Prematurity in China.

Authors:  Jing Feng; Jing Qian; Yanrong Jiang; Mingwei Zhao; Jianhong Liang; Hong Yin; Yi Chen; Wenzhen Yu; Xiaoxin Li
Journal:  Ophthalmology       Date:  2016-11-30       Impact factor: 12.079

3.  Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.

Authors:  Helen A Mintz-Hittner; Megan M Geloneck; Alice Z Chuang
Journal:  Ophthalmology       Date:  2016-05-27       Impact factor: 12.079

4.  Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab.

Authors:  Laura L Snyder; Jose Maria Garcia-Gonzalez; Michael J Shapiro; Michael P Blair
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2016-03       Impact factor: 1.300

5.  Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser.

Authors:  Kamini Raghuram; Maram Isaac; Junmin Yang; Alaa AlAli; Kamiar Mireskandari; Linh G Ly; Edmond Kelly; Rudaina Banihani; Prakesh S Shah; Nasrin Tehrani
Journal:  J Perinatol       Date:  2019-07-24       Impact factor: 2.521

Review 6.  Retinopathy of prematurity: a review of risk factors and their clinical significance.

Authors:  Sang Jin Kim; Alexander D Port; Ryan Swan; J Peter Campbell; R V Paul Chan; Michael F Chiang
Journal:  Surv Ophthalmol       Date:  2018-04-19       Impact factor: 6.048

7.  Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity.

Authors:  Yichen Bai; Huanjie Nie; Shiyu Wei; Xiaohe Lu; Xiaoyun Ke; Xuejun Ouyang; Songfu Feng
Journal:  Br J Ophthalmol       Date:  2018-07-20       Impact factor: 4.638

8.  Insights into advanced retinopathy of prematurity using handheld spectral domain optical coherence tomography imaging.

Authors:  Sai H Chavala; Sina Farsiu; Ramiro Maldonado; David K Wallace; Sharon F Freedman; Cynthia A Toth
Journal:  Ophthalmology       Date:  2009-09-18       Impact factor: 12.079

Review 9.  Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control.

Authors:  Clare Gilbert
Journal:  Early Hum Dev       Date:  2008-01-29       Impact factor: 2.079

Review 10.  Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.

Authors:  Mari Jeeva Sankar; Jhuma Sankar; Parijat Chandra
Journal:  Cochrane Database Syst Rev       Date:  2018-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.